Skip to Content
Print Share

Generic Aplenzin Availability

Aplenzin is a brand name of bupropion, approved by the FDA in the following formulation(s):

APLENZIN (bupropion hydrobromide - tablet, extended release;oral)

  • Manufacturer: VALEANT PHARMS NORTH
    Approval date: April 23, 2008
    Strength(s): 174MG [RLD], 348MG [RLD], 522MG [RLD]

Has a generic version of Aplenzin been approved?

No. There is currently no therapeutically equivalent version of Aplenzin available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aplenzin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Modified release formulations of a bupropion salt
    Patent 7,241,805
    Issued: July 10, 2007
    Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Turchetta; Stefano & Jackson; Graham & Massardo; Pietro & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories, Inc.

    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product
  • Modified release formulations of a bupropion salt
    Patent 7,569,610
    Issued: August 4, 2009
    Inventor(s): Oberegger; Werner & Maes; Paul & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International SRL

    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
  • Modified release formulations of a bupropion salt
    Patent 7,572,935
    Issued: August 11, 2009
    Inventor(s): Oberegger; Werner & Maes; Paul & Turchetta; Stefano & Massardo; Pietro & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.R.L.

    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product
  • Modified release formulations of a bupropion salt
    Patent 7,585,897
    Issued: September 8, 2009
    Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.r.l.

    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product
  • Bupropion hydrobromide and therapeutic applications
    Patent 7,645,802
    Issued: January 12, 2010
    Inventor(s): Oberegger; Werner & Maes; Paul & Saleh; Mohammad Ashty & Jackson; Graham
    Assignee(s): Biovail Laboratories International SRL.

    Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.

    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product
  • Modified release formulations of a bupropion salt
    Patent 7,649,019
    Issued: January 19, 2010
    Inventor(s): Oberegger; Werner & Zhou; Fang & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.R.L.

    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product
  • Modified release formulations of a bupropion salt
    Patent 7,662,407
    Issued: February 16, 2010
    Inventor(s): Oberegger; Werner & Maes; Paul & Jackson; Graham & Saleh; Mohammad Ashty
    Assignee(s): Biovail Laboratories International S.R.L.

    The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product
  • Bupropion hydrobromide and therapeutic applications
    Patent 7,671,094
    Issued: March 2, 2010
    Inventor(s): Williams; Robert Parry & Silverstone; Peter Harris
    Assignee(s): Biovail Laboratories International S.R.L.

    Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.

    Patent expiration dates:

    • June 27, 2026
      ✓ 
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Add to My Med List
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide